| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514413000 | Ring nitrogen is shared by the cyclos of the bicyclo ring system | 43 |
| 20080262070 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds - Tetrahydro-pyrrolizinone compounds which mediate the activity of LFA-1 with its ligands involved in cell adhesion, migration and activation. | 10-23-2008 |
| 20090042968 | THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF KETOROLAC - Therapeutic compositions, particularly sprayable aqueous compositions, comprise ketorolac or a pharmaceutically acceptable salt, in combination with a local anesthetic, such as lidocaine hydrochloride. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation and have the benefit of reduced stinging and improved efficacy, compared to known nasally administered compositions. | 02-12-2009 |
| 20090203759 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS - The present invention relates to a pharmaceutical formulation comprising:
| 08-13-2009 |
| 20090203760 | CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS - The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions. | 08-13-2009 |
| 20090209610 | Polymorphic form of 6-(4-chlorophenyl)-2,2-dimethyl-7-Phenyl-2,3-Dihydro-1h-Pyrrolizin-5-Ylac- etic Acid - The present invention relates to a new crystalline modification of 6-(4-chlorophenyl)-2,2-dmethyl-7-phenyl-2, S-dihydro-1H-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state | 08-20-2009 |
| 20090264493 | Process for Producing Aqueous Solution of Doripenem - A process for producing an aqueous solution of doripenem while decomposition of doripenem by heat is suppressed is found out. | 10-22-2009 |
| 20090326034 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 12-31-2009 |
| 20090326035 | Compositions and Methods for Preventing or Reducing Postoperative Ileus and Gastric Stasis in Mammals - Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions include a combination of a carrier component and a bioactive component which acts to prevent or reduce post-operative ileus. Such methods include administering atherapeutically effective amount of the composition directly to the serosal surfaces of the gastrointestinal and other visceral organs. | 12-31-2009 |
| 20100016402 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION - This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation. | 01-21-2010 |
| 20100081700 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 04-01-2010 |
| 20100087503 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 04-08-2010 |
| 20100099730 | ANNELLATED PYRROLE COMPOUNDS FOR CANCER MANAGEMENT - The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e.g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, actively treats, reverses or prevents any disease related to insufficient apoptosis, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purposes. | 04-22-2010 |
| 20100130580 | Formulations and Methods for Treating Dry Eye - The present invention provides compositions comprising a low dose amount of an ophthalmic NSAID for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye and safe for chronic use. | 05-27-2010 |
| 20100292289 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES - The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention. | 11-18-2010 |
| 20110021595 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises mixtures of carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye and improve visual acuity of the users. | 01-27-2011 |
| 20110046198 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 02-24-2011 |
| 20110160271 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 06-30-2011 |
| 20110275688 | KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALING - The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patient's cornea. | 11-10-2011 |
| 20110281927 | DEUTERIUM-ENRICHED DORIPENEM - The present application describes deuterium-enriched doripenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 11-17-2011 |
| 20120010261 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE - The present invention relates to the choline and tromethamine salt of Licofelone. | 01-12-2012 |
| 20120101142 | Ready to Use Ketorolac Formulations - Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising:
| 04-26-2012 |
| 20120190722 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 07-26-2012 |
| 20120196913 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 08-02-2012 |
| 20120196914 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 08-02-2012 |
| 20120329849 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION - This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation. | 12-27-2012 |
| 20120329850 | Methods for treating retinopathy with extended therapeutic effect - Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy. | 12-27-2012 |
| 20130030032 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 01-31-2013 |
| 20130059898 | 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF - Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetyl-choline receptor-mediated diseases, such as pulmonary diseases, are provided. | 03-07-2013 |
| 20130137742 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 05-30-2013 |
| 20130197051 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 08-01-2013 |
| 20130203833 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 08-08-2013 |
| 20130203834 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 08-08-2013 |
| 20130245088 | KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALING - The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patients cornea. | 09-19-2013 |
| 20130281506 | COMBINATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG WITH AN ANTI-HISTAMINIC DRUG INTENDED FOR OPHTHALMIC USE - The present invention is directed to a stable formulation of a combination of ketorolac (non-steroidal anti-inflammatory drug) with olopatadine (anti-histaminic drug) intended for ophthalmic use. This pharmaceutical composition is used for treatment of ophthalmic diseases and conditions, particularly seasonal ocular surface allergy. | 10-24-2013 |
| 20130296396 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME - The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition. | 11-07-2013 |
| 20140235691 | Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection - The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection. | 08-21-2014 |
| 20150057327 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. | 02-26-2015 |
| 20150119440 | EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF - Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. | 04-30-2015 |
| 20150141479 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating moderate to severe pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, severe pain, chronic pain, chemotherapy induced pain, epilepsy, glaucoma, arthritis, tooth aches, inflammation, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder. | 05-21-2015 |
| 20150290170 | KETOROLAC-CONTAINING SUSTAINED RELEASE DRUG DELIVERY SYSTEMS - Biodegradable intraocular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye for an extended period of time at a substantially constant rate are described. | 10-15-2015 |
| 20150314084 | DEVICE FOR INTRANASAL ADMINISTRATION - Disclosed herein are devices and processes for preparing a vial for an intranasal administration of a medicament where the vial comprises reduced oxygen content. | 11-05-2015 |
| 20150342928 | Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection - The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection. | 12-03-2015 |
| 20160136089 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION - This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation. | 05-19-2016 |
